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Slowing the aging process, delaying the onset of diseases, extending cellular life… as people grow older, they often 
seek products or therapies to try to stay young and healthy. A 
researcher in the School of Medicine at Wayne State University 
may have discovered the proverbial “fountain of youth” that 
may one day help us all to live better and happier lives.
Stanley R. Terlecky, Ph.D., associate professor of pharmacology 
in the School of Medicine has identified a novel technology 
that can reduce or even eliminate accumulation of free radicals 
or oxidants in cells long associated with the aging process. His 
research focuses on peroxisomes, essential subcellular structures 
whose critical roles in metabolism, aging, and disease have only 
recently come to light.
The technology
As we age, our cells undergo an irreversible physiological 
decline caused by a variety of factors including shortening 
of chromosome ends, DNA damage and the accumulation of 
harmful oxygen species. Peroxisomes are at the center of this 
process to an extent never before appreciated. They not only 
carry out critical cellular functions but also produce potentially 
toxic metabolites as the “spent fuel” from these reactions. 
Hydrogen peroxide is one of these harmful byproducts generated 
by peroxisomes that can be deadly to cells. 
To neutralize its toxic effects, peroxisomes pull the antioxidant 
enzyme catalase from the cytosol of the cell – the “soup” within 
which all the other cell organelles reside. A healthy peroxisome 
will then use the imported catalase to convert potentially 
dangerous hydrogen peroxide to harmless water and oxygen. 
This process can be thrown off kilter however, as cells age or 
are affected by disease or mutation. The result is that catalase 
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form which permits delivery to the lung 
as a potential treatment for this devas-
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is not properly utilized by peroxisomes, with dire 
consequences to the cell and the entire organism.
“By doing focused research on the peroxisome, 
we discovered it is a viable, druggable target,” said 
Dr. Terlecky. “Unlike mitochondria, to which you 
can’t deliver a protein directly, peroxisomes are 
mechanistically much different.” Dr. Terlecky and 
fellow expert in cellular trafficking pathways, Paul 
A. Walton, Ph.D., from the University of Western 
Ontario, created a novel protein therapeutic that 
can be delivered into a human cell and then sent to 
the peroxisome to neutralize harmful oxidants. This 
proprietary technology is called CATSKL™.
“The compound has great potential for treating 
serious health problems including ischemia-
reperfusion injury associated with heart attack 
or stroke, inflammation and related arthritic 
conditions, and type 2 diabetes, among others,” 
Terlecky commented. In addition, idiopathic 
pulmonary fibrosis kills 40,000 people per year and 
there are no cures or effective treatments. There is 
evidence the pathology is associated with excessive 
production of reactive oxygen species (i.e. oxidants). 
“We are currently examining whether or not our 
biologic can be aerolized in a form which permits 
delivery to the lung as a potential treatment for this 
devastating class of pulmonary disease,” added  
Dr. Terlecky. 
Dr. Terlecky and a team of researchers also are 
looking at other potential uses for their technology 
including treatment of a number of skin diseases 
such as psoriasis and dermatitis, as well as treating 
and protecting surrounding skin tissue exposed or 
damaged by radiation or photodynamic therapies. 
“We are also looking at CATSKL™ as a preservation 
solution,” Dr. Terlecky said. In heart, lung, 
liver, and kidney transplants, the cessation and 
subsequent commencement of blood flow causes 
reperfusion injury that result in inflammation and 
oxidative damage to the organ. “CATSKL™ may be 
able to thwart this from occurring in the transplant 
process,” he said. 
In addition to the many pharmaceutical uses, 
CATSKL™ has tremendous potential as an “active” 
component of so-called cosmeceutical products. 
It can be formulated with a number of other 
ingredients as an effective antioxidant in various 
skincare products.
Bringing CATSKL™ to life  
– EXT Life Sciences, Inc.
In 2004, Dr. Terlecky and his friend, John Tesija, 
were having a discussion about this discovery. What 
was meant to be a casual conversation turned into 
a partnership that brought EXT Life Sciences, Inc., 
“Through all of  this, I have 
learned that it takes time to de-
velop a marketable compound.”
— Dr. Stanley Terlecky
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to fruition. With Terlecky’s scientific expertise and 
Tesija’s legal and business savvy, the two became 
partners, along with Gary Novara. Tesija and Novara 
are the principle partners of Southfield’s Novara and 
Tesija, P.L.L.C., a law firm with expertise in pension 
and corporate law. Today, EXT Life Sciences, Inc. is 
working with development partners to bring their 
first product to market. 
“We are currently partnering with carefully 
selected companies to develop the product, with 
the goal of bringing an over-the-counter skin care 
product to market in 2009,” said Dr. Terlecky. 
The product will be marketed as a novel targeted 
antioxidant in a formulation specifically designed to 
prevent collagen breakdown and reduce skin aging. 
“Through all of this, I have learned that it takes 
time to develop a marketable compound,” said Dr. 
Terlecky. He welcomes the process adding, “Our 
research truly bridges the translational gap – having 
been developed in the laboratory but ultimately 
being of benefit in the clinic.” Through his 
important research, Dr. Terlecky may one day find 
potential treatments or cures for numerous skin and 
systemic pathologies, ultimately helping many in 
their fight against disease.
About Dr. Stanley Terlecky:  Dr. Terlecky received his 
B.A. in the history of art from New York University and his Ph.D. 
in cellular and molecular physiology from Tufts University. He 
joined Wayne State University in 1998 after completing an 
NIH-sponsored postdoctoral fellowship in the Department of 
Biology at the University of California, San Diego.
Dr. Stanley Terlecky, associate professor of Pharmacology 
and co-founder, EXT Life Sciences, Inc.
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